Marinomed Biotech AG confirmed its financial outlook for the fiscal year 2022: The Company expects continued growth of Carragelose revenues and a slight increase in R&D expenses, and consequently an operating loss for 2022. Marinomed plans to reach operating profitability in the medium term.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.5 EUR | 0.00% | -3.51% | -43.49% |
Apr. 16 | Transcript : Marinomed Biotech AG, 2023 Earnings Call, Apr 16, 2024 | |
Apr. 16 | Marinomed Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-43.49% | 27.63M | |
-2.32% | 92.59B | |
+3.68% | 41.43B | |
-11.44% | 33.49B | |
-19.22% | 14.62B | |
-8.95% | 12.77B | |
-11.34% | 11.58B | |
-43.53% | 11.35B | |
+3.75% | 8.97B | |
-6.32% | 8.3B |
- Stock Market
- Equities
- MARI Stock
- News Marinomed Biotech AG
- Marinomed Biotech AG Confirms Financial Outlook for the Fiscal Year 2022